Shom Goel

9.9k total citations · 5 hit papers
71 papers, 5.8k citations indexed

About

Shom Goel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Shom Goel has authored 71 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Shom Goel's work include Advanced Breast Cancer Therapies (38 papers), HER2/EGFR in Cancer Research (28 papers) and Cancer Treatment and Pharmacology (16 papers). Shom Goel is often cited by papers focused on Advanced Breast Cancer Therapies (38 papers), HER2/EGFR in Cancer Research (28 papers) and Cancer Treatment and Pharmacology (16 papers). Shom Goel collaborates with scholars based in United States, Australia and France. Shom Goel's co-authors include Rakesh K. Jain, Dai Fukumura, Dan G. Duda, Jean J. Zhao, Yves Boucher, Lei Xu, Lance L. Munn, Sandra S. McAllister, Molly J. DeCristo and Yuhui Huang and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Shom Goel

70 papers receiving 5.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

2011 1.2k citations Shom Goel, Rakesh K. Jain et al. profile →
CDK4/6 inhibition triggers anti-tumour immunity

2017 998 citations Shom Goel, Molly J. DeCristo et al. Nature profile →
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

2013 517 citations Shom Goel, Rakesh K. Jain et al. Cancer Research profile →
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest

2018 332 citations Shom Goel, Molly J. DeCristo et al. profile →
Targeting CDK4 and CDK6 in cancer

2022 281 citations Shom Goel, Johann S. Bergholz et al. Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Shom Goel

Since Specialization

Citations

This map shows the geographic impact of Shom Goel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shom Goel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shom Goel more than expected).

Fields of papers citing papers by Shom Goel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shom Goel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shom Goel. The network helps show where Shom Goel may publish in the future.

Co-authorship network of co-authors of Shom Goel

This figure shows the co-authorship network connecting the top 25 collaborators of Shom Goel. A scholar is included among the top collaborators of Shom Goel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shom Goel. Shom Goel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer 2025 ·Clinical Cancer Research ·Shom Goel, Bojana Jovanović, (unknown), Melissa E. Hughes, (unknown), (unknown), (unknown), Eileen Wrabel, Rinath Jeselsohn, Nancy U. Lin, Nabihah Tayob, Elizabeth A. Mittendorf, Stuart J. Schnitt, Sara M. Tolaney	3
2	Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer 2025 ·Journal for ImmunoTherapy of Cancer ·Ana C. Garrido-Castro, Noah Graham, Lestat R. Ali, Christina I. Herold, (unknown), Khanh Do, Heather A. Parsons, Tianyu Li, Shom Goel, (unknown), Eileen Wrabel, Amy J. Williams, (unknown), Elizabeth A. Mittendorf, Stephanie K. Dougan, Nabihah Tayob, Geoffrey I. Shapiro, Sara M. Tolaney	5
3	485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+/HER2+ metastatic breast cancer (MBC) 2025 ·Annals of Oncology ·Inês Vaz-Luís, Graziella Mazza, (unknown), (unknown), (unknown), (unknown), Angela DeMichele, Briant Fruth, Xavier González, Prudence A. Francis, (unknown), (unknown), Suzette Delaloge, Kathy D. Miller, EP Winer, Sumithra J. Mandrekar, Shom Goel, (unknown), (unknown), Otto Metzger	1
4	Intracellular zinc protects tumours from T cell-mediated cytotoxicity 2024 ·Cell Death and Differentiation ·Emily J. Lelliott, (unknown), Katherine Ganio, Jessica Michie, Shelly Wang, (unknown), Natasha Silke, Antonio Ahn, Kelly M. Ramsbottom, A. J. Brennan, Andrew J. Freeman, Shom Goel, Stephin J. Vervoort, Conor J. Kearney, Paul A. Beavis, Christopher A. McDevitt, John Silke, Jane Oliaro	3
5	Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies 2024 ·Clinical Cancer Research ·Bojana Jovanović, S. Church, (unknown), Khrystyna North, Edward T. Richardson, (unknown), Victoria Attaya, (unknown), (unknown), Gregory J. Kirkner, Melissa E. Hughes, Nancy U. Lin, Elizabeth A. Mittendorf, Stuart J. Schnitt, Sara M. Tolaney, Shom Goel	3
6	Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients 2023 ·Clinical Cancer Research ·Sara M. Tolaney, Shom Goel, Jorge Nadal, Hannelore Denys, Manuel Ruíz Borrego, Lacey M. Litchfield, Jiangang Liu, Adams K. Appiah, Yanyun Chen, Fabrice André	10
7	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study 2023 ·Future Oncology ·Sara M. Tolaney, Shom Goel, Adams K. Appiah, (unknown), Yanyun Chen, Fabrice André	1
8	INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors 2023 ·Cancer Discovery ·(unknown), (unknown), Antonio Ahn, Michael Taylor, (unknown), Keefe T. Chan, Kun‐Hui Lu, (unknown), (unknown), Rhiannon Coulson, Susanne Ramm, April C. Watt, (unknown), John Bisi, Jay C. Strum, Patrick J. Roberts, Shom Goel	62
9	Emerging Therapies for Breast Cancer 2022 ·Cold Spring Harbor Perspectives in Medicine ·Shom Goel, Sarat Chandarlapaty	9
10	Targeting CDK4 and CDK6 in cancer breakdown → 2022 ·Nature reviews. Cancer ·Shom Goel, Johann S. Bergholz, Jean J. Zhao	281
11	Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity 2019 ·JACC Heart Failure ·Shom Goel, Jia Liu, Hao Guo, William T. Barry, Richard H. Bell, (unknown), Jodi Lynch, Patricia Bastick, Lorraine A. Chantrill, Belinda E. Kiely, Ehtesham Abdi, (unknown), Ray Asghari, (unknown), Michelle Harrison, Maija R.J. Kohonen‐Corish, Jane Beith	30
12	Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell–Mediated Immunotherapy 2017 ·Cancer Research ·Yang Zhao, Ka Ka Ting, Jia Li, Victoria C. Cogger, Jinbiao Chen, Anna Johansson, Shin Foong Ngiow, Jeff Holst, Georges E. Grau, Shom Goel, (unknown), Elisabetta Dejana, Geoffrey W. McCaughan, Mark J. Smyth, Ruth Ganß, Mathew A. Vadas, Jennifer R. Gamble	50
13	CDK4/6 inhibition triggers anti-tumour immunity breakdown → 2017 ·Nature ·Shom Goel, Molly J. DeCristo, April C. Watt, (unknown), Jaclyn Sceneay, (unknown), Naveed Khan, Jessalyn M. Ubellacker, Shaozhen Xie, Otto Metzger, Jeremy Hoog, Matthew J. Ellis, X. Cynthia, Susanne Ramm, Ian E. Krop, Eric P. Winer, Thomas M. Roberts, Hye Jung Kim, Sandra S. McAllister, Jean J. Zhao	998
14	CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure 2017 ·Current Breast Cancer Reports ·Ana C. Garrido-Castro, Shom Goel	53
15	monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+ advanced breast cancer 2016 ·Annals of Oncology ·Sara M. Tolaney, Nawel Bourayou, Shom Goel, Tammy Forrester, Fabrice André	2
16	POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer. 2015 ·PubMed ·Shom Goel, Eric P. Winer	2
17	Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer 2011 ·Asia-Pacific Journal of Clinical Oncology ·Shom Goel, R. J. Simes, Jane Beith	23
18	Final phase II results of NCI 6981: A phase I/II study of sorafenib (S) plus gemcitabine (GEM) and capecitabine (CAP) for advanced renal cell carcinoma (RCC). 2011 ·Journal of Clinical Oncology ·(unknown), (unknown), Naveed Akhtar, Shom Goel, (unknown), (unknown), Himisha Beltran, Mathew I. Milowsky, Madhu Mazumdar, James R. Wright, David M. Nanus	2
19	Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease 2011 ·Cold Spring Harbor Perspectives in Medicine ·Shom Goel, Hon Kit Wong, Rakesh K. Jain	255
20	Randomized cross‐over trial comparing inpatient and outpatient administration of high‐dose cisplatin 2010 ·Internal Medicine Journal ·(unknown), Shom Goel, (unknown), Michael Boyer, Philip Beale, R. J. Simes, Martin R. Stockler	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact